The effect of piroxicam on the prevention of postoperative retrosternal and pericardial adhesions

Simple item page
dc.contributor.authorIskesen I.
dc.contributor.authorAksoy O.
dc.contributor.authorCerrahoglu M.
dc.contributor.authorSirin H.
dc.date.accessioned2024-07-22T08:22:37Z
dc.date.available2024-07-22T08:22:37Z
dc.date.issued2007
dc.description.abstractBackground - The presence of adhesions after heart operations increases the risk of life-threatening damage to the heart and extracardiac grafts. Infections, tissue injury and inflammations are sus-pected aetiologic agents. The main purpose of our study is to evaluate the effect of an antiinflammatory agent piroxicam on the formation of retrosternal and pericardial adhesions in a rabbit model. Material and methods - 23 of forty-two New Zealand white rabbits were labelled as group P (piroxicam group) and the others as group C (n = 19, control group). All animals were subjected to median sternotomy and abrasion was applied to the epicardium and pericardium. Piroxicam was given only to group P animals 10 mg/kg/day intramuscularly on the day of operation and twice daily for 2 days postoperatively. All animals were sacrificed on the 10th postoperative day. After cardiectomy, the pericardium was totally excised; retrosternal and pericardial adhesions were evaluated and scored. t-PA (tissue plasminogen activator), PAI-I (plasminogen activator inhibitor-1) levels and pericardial tissue myeloperoxidase activities were measured. Results - More severe retrosternal and pericardial adhesions were observed in the control group (P < 0.05). Mean levels of t-PA were higher in the study group than in the control group (P < 0.05). Mean levels of PAI-I were lower in the study group (P < 0.05). Hence pericardial fibrinolytic capacity was significantly higher in the piroxicam group than in the control group. Myeloperoxidase activities in the pericardium were significantly lower in the study group than in the control group (P < 0.05). Conclusion - The use of piroxicam in the perioperative period prevents inflammation, preserves the fibrinolytic capacity of the pericardium and decreases the postoperative pericardial and retrosternal adhesions.
dc.identifier.DOI-ID10.2143/AC.62.6.2024014
dc.identifier.issn00015385
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19166
dc.language.isoEnglish
dc.subjectAdhesions
dc.subjectAnimals
dc.subjectAnti-Inflammatory Agents, Non-Steroidal
dc.subjectCardiac Surgical Procedures
dc.subjectDisease Models, Animal
dc.subjectPericarditis
dc.subjectPiroxicam
dc.subjectPostoperative Complications
dc.subjectRabbits
dc.subjectRandom Allocation
dc.subjectmyeloperoxidase
dc.subjectpiroxicam
dc.subjectplasminogen activator inhibitor 1
dc.subjecttissue plasminogen activator
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectarticle
dc.subjectcontrolled study
dc.subjectdrug effect
dc.subjectenzyme activity
dc.subjectfibrinolysis
dc.subjectheart rate
dc.subjectnonhuman
dc.subjectpericardial disease
dc.subjectpostoperative complication
dc.subjectrabbit
dc.subjectscoring system
dc.subjectsternotomy
dc.subjectthorax disease
dc.titleThe effect of piroxicam on the prevention of postoperative retrosternal and pericardial adhesions
dc.typeArticle

Files

Collections

Scopus Koleksiyonu